Antibe Therapeutics Inc.
Other OTCTotal Valuation
Antibe Therapeutics Inc. carries a market capitalization of 11.43M, placing it among publicly traded companies globally. Its enterprise value stands at 22.68M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 11.43M |
| Enterprise Value | 22.68M |
Share Statistics
Antibe Therapeutics Inc. currently has 52.67M shares outstanding.
| Shares Outstanding | 52.67M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
| PE Ratio | N/A |
| PS Ratio | N/A |
| PB Ratio | -12.23 |
| P/TBV Ratio | -114.65 |
| P/FCF Ratio | -2.61 |
| P/OCF Ratio | -2.61 |
Financial Position
Antibe Therapeutics Inc. maintains a current ratio of 10.06, meaning it holds 10.1x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 10.06 |
| Quick Ratio | 9.45 |
| Debt / Equity | N/A |
| Debt / EBITDA | N/A |
| Interest Coverage | -2,488.37 |
Financial Efficiency
| Return on Equity (ROE) | -452.98 |
| Return on Assets (ROA) | -28.52 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | N/A |
Stock Price Statistics
Antibe Therapeutics Inc.'s stock has declined approximately -0.18518519% over the past 52 weeks. The 50-day moving average sits at 0.22, while the 200-day moving average is 0.22.
| Beta (5Y) | N/A |
| 52-Week Price Change | -0.18518519% |
| 50-Day Moving Average | 0.22 |
| 200-Day Moving Average | 0.22 |
| Average Volume (20 Days) | N/A |
Income Statement
EBITDA reached -19.91M, while operating income came in at -19.91M.
| Revenue | N/A |
| Gross Profit | N/A |
| Operating Income | -19.91M |
| Pretax Income | -17.24M |
| Net Income | -18.55M |
| EBITDA | -19.91M |
| EBIT | -19.91M |
| Earnings Per Share (EPS) | -0.35 |
Balance Sheet
Total book value stands at -3.89M, with working capital of 25.30M providing operational flexibility.
| Cash & Cash Equivalents | 24.91M |
| Total Debt | N/A |
| Net Debt | -11.34M |
| Equity (Book Value) | -3.89M |
| Book Value Per Share | -0.07 |
| Working Capital | 25.30M |
Cash Flow
Antibe Therapeutics Inc. produced -18.24M in operating cash flow over the past twelve months. After subtracting 2,000.00 in capital expenditures, free cash flow totaled -18.24M - equivalent to -0.35 per share.
| Operating Cash Flow | -18.24M |
| Capital Expenditures | 2,000.00 |
| Free Cash Flow | -18.24M |
| FCF Per Share | -0.35 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | -0.33 |
| FCF Yield | -38.35 |
Stock Splits
Antibe Therapeutics Inc.'s most recent stock split took place on December 1, 2020 with a 10:1 split ratio.
| Last Split Date | 12/1/2020 |
| Split Ratio | 10:1 |
Scores
Antibe Therapeutics Inc. posts an Altman Z-Score of -7.03, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | -7.03 |